Highest-materiality recent filing
Alaunos acquires Velaris; PIPE raises ~$350M; board and charter overhaul set for vote
Alaunos acquired Velaris on Oct. 13, 2026; issued Velaris holders 105,286 Series B and 33,054 Series C preferred shares, each convertible into 1,000 common shares.
Alaunos Therapeutics gets Nasdaq delisting notice over $2.5M equity rule; plans hearing
Nasdaq staff notified Alaunos on Oct. 5, 2026 that its securities are subject to delisting for failing Listing Rule 5550(b)(1), the $2,500,000 minimum stockholders' equity requirement.
Alaunos raises $1.12M in registered direct offering of stock and pre-funded warrants
Sold 380,469 common shares at $1.46/share and 386,654 pre-funded warrants at $1.459 each for ~$1.12M gross.
Alaunos Therapeutics reduces stockholder quorum requirement to one-third of voting power
Board adopted Second Amended and Restated By-Laws effective September 16, 2026.
48-day DIO mouse study: ALN1003-treated animals had lower liver weight after adjusting for body fat (ANCOVA p=0.000005; HC3 robust p=0.000015).
Alaunos reports ALN1003 preclinical data: -12.9% weight loss, liver weight -43%; cash only $0.35M
ALN1003 in DIO mice: mean body weight change -12.9% by Day 33 and -10.3% by Day 48 (p<0.0001).
Alaunos announces preclinical ALN1003 data; cash only $0.354M, runway into Q2 2026
ALN1003 showed significantly lower HOMA-IR (p=0.0006) and higher adiponectin-to-leptin ratio in DIO mouse models.
Alaunos Therapeutics receives Nasdaq delisting notice for equity shortfall; 45 days to submit plan
Nasdaq notified Alaunos on April 9, 2026, of non-compliance with minimum $2.5M stockholders' equity; 2025 10-K reported $2.153M.
Alaunos reports positive preclinical data for ALN1003; weight loss up to 12.9% in DIO mice
ALN1003 showed dose-dependent body weight loss: -12.9% peak (Day 34) and -10.3% after 48 days vs DIO control (p<0.0001).
Alaunos reports positive preclinical obesity data but cash runway only through Q1 2026
Preclinical DIO mouse study shows statistically significant dose-related weight loss and improved body composition; lead compound identified.
Alaunos Therapeutics settles unpaid invoices with MD Anderson for $285,055
Settlement resolves disputes over $285,055 in unpaid invoices under 2019 R&D agreement with MD Anderson.
Alaunos regains Nasdaq compliance after reporting $3.66M equity in Q2 2025
Nasdaq notified Alaunos of compliance on August 19, 2025, following prior stockholders' equity deficiency.
Alaunos Therapeutics Corporate Secretary Melinda Lackey to depart August 15, 2025
Melinda Lackey notified company on 7/16/2025 of termination of consulting agreement effective 8/15/2025.
Alaunos Therapeutics appoints Michael A. Jerman as director, effective July 15, 2025
Jerman fills vacancy from Dale Curtis Hogue's resignation; also joins Audit and Compensation Committees.
Alaunos shareholders approve 10x increase in authorized common shares, reverse split authorization
Stockholders approved increasing authorized common shares from 5M to 50M; amendment effective July 10, 2025.
Dale Curtis Hogue Jr. resigned as CEO and director effective July 1, 2025; no disagreement.
Alaunos Therapeutics raises $850K via private placement of Series A-2 Convertible Preferred Stock
Aggregate purchase price of $850,000 from accredited investors; offering closed June 24, 2025.
Alaunos Therapeutics raises ~$2.05M in registered direct offering of stock and pre-funded warrants
338,725 shares at $3.36; 271,674 pre-funded warrants at $3.359/share.
Alaunos Therapeutics amends warrant with Mast Hill Fund, adds $0.57 floor price
Added floor price of $0.57 per share to exercise price adjustments in warrant issued May 19, 2025.
Alaunos Therapeutics enters $25M equity purchase agreement with Mast Hill Fund
Mast Hill commits to buy up to $25M of common stock over 24 months at Company's discretion.
Director Robert Hofmeister resigns from Alaunos Therapeutics board effective April 15, 2025
Robert Hofmeister, Ph.D., resigned from the board with immediate effect on April 15, 2025.
Alaunos directors convert $139K deferred fees to equity: shares + options
Total deferred board service fees of $139,000 from Q3 2024 through Q1 2025 converted to equity.
Alaunos raises $500K via Series A-1 Convertible Preferred to Watermill Asset Management
500 shares of Series A-1 Convertible Preferred at $1,000/share sold to Watermill Asset Management for $500K total.
Alaunos receives Nasdaq deficiency notice for equity below $2.5M minimum; 45 days to submit plan
Stockholders' equity of $2.063M as of Dec 31, 2024, falls short of Nasdaq's $2.5M minimum under Rule 5550(b)(1).
Terminated Amended and Restated License Agreement with Precigen effective Oct 4, 2024; Sleeping Beauty patent expiry in 2026 cited.
Alaunos Therapeutics to effect 1-for-10 reverse stock split effective July 17, 2024
Reverse split at 1-for-10 ratio; effective 5:00 p.m. Eastern on July 17, 2024.
Reverse stock split at ratio 1-for-10; effective July 17, 2024 at 5:00 p.m. ET.
Alaunos Therapeutics to effect 1-for-10 reverse stock split on July 17, 2024
Board approved 1-for-10 reverse split; authorized by shareholders on June 6, 2024.
Alaunos Therapeutics effects 1-for-10 reverse stock split effective July 17, 2024
Reverse split effective July 17, 2024 at 5:00 PM ET; every 10 pre-split shares become 1 post-split share.
Alaunos Therapeutics dismisses RSM, engages Cherry Bekaert as auditor
Dismissed RSM US LLP as independent auditor on June 19, 2024; no disagreements reported.
Alaunos shareholders approve reverse stock split (1:5-1:15) and authorized share increase to 50M
Stockholders approved reverse stock split at ratio between 1-for-5 and 1-for-15, at Board's discretion, effective June 12, 2024.
Michael Wong resigned as VP Finance effective Feb 23, 2024.
Alaunos Therapeutics regains Nasdaq minimum bid price compliance; panel monitor for one year
Nasdaq notified Alaunos on Feb 16, 2024 that it has regained compliance with the $1.00 bid price requirement.
Alaunos Therapeutics effects 1-for-15 reverse stock split effective Jan 31, 2024
Reverse stock split at a ratio of 1-for-15, effective January 31, 2024 at 5:00 p.m. ET.
Alaunos Therapeutics approves 1-for-15 reverse stock split effective Jan 31, 2024
Reverse split ratio of 1-for-15 approved by Board on Jan 29, 2024; effective Jan 31 at 5:00 PM ET.
Alaunos Therapeutics names Dale Hogue as Interim CEO, effective Jan 20, 2024
Dale Curtis Hogue, Jr. appointed Interim CEO; will continue serving on the Board.
Alaunos appoints new director, cash runway into Q3 2024, plans reverse stock split
Dale Curtis Hogue, Jr. appointed independent director effective Dec 29, 2023; receives initial 150k option grant vesting over 36 months.
CEO Kevin S. Boyle terminated effective Dec 22, 2023; separation payment ~$331,990 (six months base salary + COBRA).
Director Mary Thistle resigns from Alaunos Therapeutics board
Mary Thistle resigned as board member effective December 18, 2023.
Alaunos terminates SVP Legal and VP R&D; execs receive separation payments, consulting
Melinda Lackey (SVP, Legal) and Drew Deniger (VP, R&D) terminated without cause, effective Nov 15, 2023.
Alaunos receives Nasdaq delisting notice; Q3 net loss $8.5M; exploring strategic alternatives
Nasdaq determined to delist TCRT because bid price was below $0.10 for 10 consecutive days; suspension effective Nov 17, 2023.
Alaunos Therapeutics Chairman James Huang resigns; Holger Weis elected successor
James Huang resigned as Chairman and board member effective September 22, 2023.
Alaunos Therapeutics winds down TCR-T trial, cuts workforce 60%, explores strategic alternatives
Q2 2023 net loss $8.8M ($0.04 per share); cash $18.3M, expected to fund ops into Q4 2023.
Transfer of Common Stock listing from Nasdaq Global Select to Capital Market approved July 5, effective July 7, 2023.
Alaunos Therapeutics stockholders approve reverse stock split and increase in authorized shares
Stockholders approved a reverse stock split at a ratio of 1-for-5 to 1-for-15, at Board discretion (141.4M for, 38.5M against).
Alaunos Q1 net loss $10M; debt-free after SVB loan prepayment; expects interim TCR-T data Q3
Net loss of $10.0M ($0.04/share) vs $9.8M ($0.05) in Q1 2022; R&D expenses up 17% to $6.5M.
Alaunos amends license with Precigen; returns CAR/IL-12 rights, eliminates all payment obligations
Alaunos returns exclusive rights to CAR (CD19 & BCMA) and IL-12 products to Precigen; retains TCR and Sleeping Beauty licenses.
Third Amendment to Loan & Security Agreement, effective March 30, 2023.
Alaunos Therapeutics appoints Dr. Robert Hofmeister to board, replacing Dr. Christopher Bowden
Christopher Bowden resigned from board effective March 30, 2023; no disagreement with company.
Alaunos reports Q4 2022 net loss $9.2M, cash $53M; TCR library expanded
Net loss $9.2M in Q4 2022 ($0.04/share) vs $11.8M ($0.05) prior year; full year loss $37.7M.
In accordance with the Merger Agreement, on October 13, 2026, effective immediately after the effective time of the Second Merger, Peter Harwin was appointed to the Board as a director.
In accordance with the Merger Agreement, on October 13, 2026, each of Robert W. Postma, Michael A. Jerman and Jaime W. Vieser delivered resignations that will become effective automatically only upon, and subject to, stockholder approval of the Conversion Proposal. None of the resignations were as a result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
In accordance with the Merger Agreement, on October 13, 2026, each of Robert W. Postma, Michael A. Jerman and Jaime W. Vieser delivered resignations that will become effective automatically only upon, and subject to, stockholder approval of the Conversion Proposal. None of the resignations were as a result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
In accordance with the Merger Agreement, on October 13, 2026, each of Robert W. Postma, Michael A. Jerman and Jaime W. Vieser delivered resignations that will become effective automatically only upon, and subject to, stockholder approval of the Conversion Proposal. None of the resignations were as a result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Robert Hofmeister, Ph.D. Resignation On April 15, 2025, Dr. Hofmeister resigned as a member of the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect.
On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, of Alaunos Therapeutics, Inc. (the "Company"), effective February 23, 2024.
On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement (the “Consulting Agreement”), effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s Vice President, Finance.
On January 20, 2024, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer of the Company, effective January 20, 2024.
On December 29, 2023, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as a director of the Company, effective immediately.
Pursuant to the terms of his employment agreement, upon his termination Mr. Boyle was deemed to automatically resign from the Company’s board of directors.
On December 22, 2023, Alaunos Therapeutics, Inc. (the “Company”) entered into a Separation and Release Agreement, effective December 22, 2023, with Kevin S. Boyle, Sr. (the “Separation Agreement”), the Company’s Chief Executive Officer, in connection with Mr. Boyle’s termination.
On December 18, 2023, Mary Thistle resigned as a member of the board of directors of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect.
Max materiality 0.85 · Median 0.60 · Most common event other_material